NCOA2
NCOA2 (Nuclear receptor coactivator 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Lung cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Transcriptional coactivator for steroid receptors and nuclear receptors. Coactivator of the steroid binding domain (AF-2) but not of the modulating N-terminal domain (AF-1). Required with NCOA1 to control energy balance between white and brown adipose tissues. Critical regulator of glucose metabolism regulation, acts as a RORA coactivator to specifically modulate G6PC1 expression. Involved in the positive regulation of the transcriptional activity of the glucocorticoid receptor NR3C1 by sumoylation enhancer RWDD3. Positively regulates the circadian clock by acting as a transcriptional coactivator for the CLOCK-BMAL1 heterodimer. Location: Nucleus (UniProt). Locus 8q13.3 (HGNC).
- Oesophageal cancer: Open Targets association 0.51 with oesophageal cancer (MONDO_0007576); IntOGen driver in 1 cohort (ESCA)
- Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD)
- Lung cancer: Open Targets association 0.57 with lung cancer (MONDO_0008903)
- Breast cancer: Open Targets association 0.56 with breast cancer (MONDO_0007254)
- Sarcomas: Open Targets association 0.56 with sarcoma (MONDO_0005089)
- Prostate cancer: Open Targets association 0.52 with prostate cancer (MONDO_0008315)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"NCOA2" OR ABSTRACT:"NCOA2" OR TITLE:"nuclear receptor coactivator 2" OR ABSTRACT:"nuclear receptor coactivator 2" OR TITLE:"Nuclear receptor coactivator 2" OR ABSTRACT:"Nuclear receptor coactivator 2" OR TITLE:"SRC-2" OR ABSTRACT:"SRC-2" OR TITLE:"TIF2" OR ABSTRACT:"TIF2" OR TITLE:"GRIP1" OR ABSTRACT:"GRIP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NCOA2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ncoa2.json. Licence CC BY-NC 4.0.